In Re Relafen Antitrust Litigation
States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.
Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
Missouri, et al vs. Arch Coal, Inc and New Vulcan Coal Holdings, LLC and Triton Coal Company, LLC, US District Court, District of Columbia – No. 1:04CV00535
Merger review of two of the most dominant coal producers in the Permian Basin.
In re Antibiotic Antitrust Actions, 410 F. Supp. 669, 1974 U.S. Dist. LEXIS 9407 (D. Minn. 1974)
Plaintiff States sought damages and injunctive relief, alleging that Defendant companies conspired to monopolize and restrain the trade for the manufacture, sale and distribution of broad spectrum antibiotics (BSA).
New York v. Microsoft Corp., 97 F. Supp. 2d 59 (D.D.C. 2000)
U.S. Department of Justice and the Plaintiff States alleged that the Defendant, Microsoft Corporation violated State and Federal law by maintaining a monopoly in the market for Intel-compatible personal computer operating systems and by illegally tying its Windows operating system to its Internet Explorer browser.
Texas v. Zeneca, 1997 U.S. Dist. LEXIS 13153 (N.D. Tex. 1997)
States sought an injunction and monetary damages from Zeneca, Inc. (Zeneca), alleging that the company conspired with distributors of its crop protection chemicals to maintain the resale price of the chemicals.
In re Clozapine Antitrust Litigation, MDL No. 874 (N.D. Ill. 1991)
Plaintiff States sought monetary damages and injunctive relief against Sandoz Pharmaceuticals Corporation (Sandoz), alleging the company unlawfully required those who purchased its drug, Clozapine, to also purchase distribution and patient monitoring services from Sandoz.
In re Compact Disc Minimum Advertised Price Antitrust Litigation MDL No. 1361 (D. Me. 2002) MDL-1391; No. 00-CIV-5853 (BSJ) (S.D.N.Y Aug. 8, 2000) (complaint)
Plaintiff States sought damages and injunctive relief, alleging that Defendant CD distributors unlawfully conspired to implement stringent minimum advertised price (MAP) policies in violation of antitrust laws.
In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb
Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.
In re Disposable Contact Lens Antitrust Litigation, 2001-1 Trade Cas. (CCH) & 73,150
Plaintiff States sought damages and injunctive relief against the three major contact lens makers and the American Optometric Association. The States alleged that defendants conspired to cut mail order companies and pharmacies out of the market for replacement contact lenses.
